Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-ketoepoxide group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dom...

Disclosed herein are carbonyl compounds of having the structural formula: ##STR00001## or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, an...

Lung disease, such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), asthma or acute and chronic bronchitis, can be treated with an oxyamide-containing compound.

Peptides derived from a segment of human histone H2A, the segment corresponding to amino acid residues 36-44 of human histone H2A, are capable of reducing or ameliorating the extent of injury induced by noxious stimuli when administered to animals. Pharmaceutical compositions and methods of using these peptides are also disclosed. The pharmaceutical compositions according to the invention are useful for treating and protecting against inflammatory diseases, autoimmune diseases, for treating and ...

One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

This invention comprises the novel compounds of formula (I) wherein n, R.sup.1, R.sup.2, R.sup.3, R.sup.4, L, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine. ##STR00001##

Compounds represented by formula (1) have strong inhibitory activity that is selective towards HDAC1 and HDAC4. Therefore, the compounds of the present invention are useful as pharmaceutical agents for treating or preventing diseases caused by HDAC1 and HDAC4. ##STR00001##

This invention comprises the novel compounds of formula (I) ##STR00001## wherein n, m, t, R.sup.1, R.sup.2, L, Q, X, Y, Z and ##STR00002## have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

The present invention relates to a chimeric gene for conferring to plants an increased tolerance to a herbicide. This chimeric gene comprises, in the direction of transcription, a promoter region, a transit peptide region, a sequence encoding glyphosate tolerance and a polyadenylation signal region, wherein the promoter region consists of at least one promoter of a plant histone gene enabling the expression of the herbicide tolerance protein in the regions of glyphosate accumulation. The present...

The present invention relates to: 1) A monoclonal antibody (mAb) that binds selectively to phosphorylated histone H1 and not to nonphosphorylated histone H1 and its use. In one embodiment, the mAb of the present invention binds selectively to histone H1 phosphorylated at the 12D11 epitope as defined herein, and 2) A cell producing a monoclonal antibody which binds selectively to phosphorylated histone H1 and has been shown to distinguish between histone H1 phosphorylated at the 12D11 epitope and...